Ms. Arianne Susan Jong, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 903 Medical Center Dr, Arlington, WA 98223 Phone: 360-435-0242 Fax: 360-435-9135 |
Grace Bay, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 903 Medical Center Dr, Arlington, WA 98223 Phone: 360-435-0242 Fax: 360-435-9135 |
Dr. Ann Aileen Hoffman, D.O. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 903 Medical Center Dr, Arlington, WA 98223 Phone: 360-435-0242 Fax: 360-435-9135 |
David Melvin Gran, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 903 Medical Center Dr, Arlington, WA 98223 Phone: 360-435-0242 |
Dr. Ralph Narinedhat, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 903 Medical Center Dr, Arlington, WA 98223 Phone: 360-435-0242 Fax: 360-435-9135 |
News Archive
Laparoscopic cholecystectomy is a minimally invasive procedure for gallbladder removal, and one of the most common surgical procedures worldwide. While the procedure has a very high success rate, 1 in 200 patients will sustain serious bile duct injury, primarily due to misidentification of the biliary anatomy. With 800,000 procedures carried out in the United States each year, that means in the U.S. alone 4,000 patients will be seriously injured.
Silvana L. Costa, PhD, of Kessler Foundation has been awarded a Switzer Research Fellowship by the National Institute on Disability, Independent Living and Rehabilitation Research. The $70,000 Merit Award funds her research on "Processing Speed Deficits in Multiple Sclerosis: Exploring the Complex Sensorial Cognitive Motor Interaction."
Results of a new study strongly suggest that DN-101, a new high-dose calcitriol pill designed specifically as a cancer therapy, given in combination with docetaxel (Taxotere) extends the lives of men with advanced prostate cancer.
YM BioSciences Inc., today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011.
FemOne, Inc., a publicly held Nevada Corporation, announced that it has successfully finished testing, and is getting ready to launch new applications for its revolutionary quantum-physics based technology named "BIOTRON".
› Verified 6 days ago